Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Immix Biopharma is a clinical-stage biopharmaceutical company developing innovative cell therapies, primarily CAR-T, for light chain (AL) Amyloidosis and immune-mediated diseases. Its lead candidate, NXC-201, targets relapsed/refractory AL Amyloidosis, with ongoing clinical trials and regulatory designations including Orphan Drug and RMAT. The company focuses on leveraging proprietary platforms to create accessible, targeted treatments for serious, underserved conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.